Dr. Chang-Ning Liu is a Principal Scientist in the Worldwide Research and Development of Pfizer Inc. Prior to joining Pfizer in 2002, he served as an Associate Research Scientist at Neurology Department of Yale University School of Medicine (2000-2002) and completed a Golda Meir postdoctoral fellowship at Hebrew University of Jerusalem (1997-2000). He received his Doctorate degree in neuroscience from China Academy of Chinese Medical Sciences in 1994, Master’s degree in animal physiology and biochemistry in 1986 and Bachelor’s degree in veterinary medicine in 1983. His research interests include in vivo, ex vivo and in vitro modeling to address efficacy and toxicity of small molecule and biologic drug candidates during drug discovery and preclinical development, using electrophysiology, imaging and other state-of-the-art techniques. With experience in study directing of over 20 rodent and non-rodent studies, he is also familiar with assessment of drug toxicity in preclinical toxicology studies for regulatory purpose. He published over 20 original research papers in peer-reviewed pharmacology, toxicology, pain and neuroscience journals, presented more than 30 abstracts/posters in national and international academic conferences, and serve as editor/reviewer for over 10 close-access and open-access journals

Dr. Chang-Ning Liu research interest are(1) Animal modeling of pain, peripheral neuropathy, retinal injury and arthritis. (2) Mechanisms and de-risking strategies of neurotoxicity, ocular toxicity and musculoskeletal toxicity caused by large and small molecular drug candidates.